Rapid lc-ms drug metabolite profiling using microsomal enzyme bioreactors in a parallel processing format
View/ Open
Full Text
Date
2009-12-15Author
Bajrami, Besnik
Zhao, Linlin
Schenkman, John B.
Rusling, James F.
Metadata
Show full item recordUsage
This item's downloads: 0 (view details)
Cited 26 times in Scopus (view citations)
Recommended Citation
Bajrami, Besnik; Zhao, Linlin; Schenkman, John B. Rusling, James F. (2009). Rapid lc-ms drug metabolite profiling using microsomal enzyme bioreactors in a parallel processing format. Analytical Chemistry 81 (24), 9921-9929
Published Version
Abstract
Silica nanoparticle bioreactors featuring thin films of enzymes and polyions were utilized in a novel high-throughput 96-well plate format for drug metabolism profiling. The utility of the approach was illustrated by investigating the metabolism of the drugs diclofenac (DCF), troglitazone (TGZ), and raloxifene, for which we observed known metabolic oxidation and bioconjugation pathways and turnover rates. A broad range of enzymes was included by utilizing human liver (HLM), rat liver (RLM) and bicistronic human-cyt P450 3A4 (bicis center dot-3A4) microsomes as enzyme sources. This parallel approach significantly shortens sample preparation steps compared to an earlier manual processing with nanoparticle bioreactors, allowing a range of significant enzyme reactions to be processed simultaneously. Enzyme turnover rates using the microsomal bioreactors were 2-3 fold larger compared to using conventional microsomal dispersions, most likely because of better accessibility of the enzymes. Ketoconazole (KET) and quinidine (QIN), substrates specific to cyt P450 3A enzymes, were used to demonstrate applicability to establish potentially toxic drug-drug interactions involving enzyme inhibition and acceleration.